[go: up one dir, main page]

CY1119488T1 - Παραγων για θεραπεια ή/και αποτροπη διαταραχης υπνου - Google Patents

Παραγων για θεραπεια ή/και αποτροπη διαταραχης υπνου

Info

Publication number
CY1119488T1
CY1119488T1 CY20171101091T CY171101091T CY1119488T1 CY 1119488 T1 CY1119488 T1 CY 1119488T1 CY 20171101091 T CY20171101091 T CY 20171101091T CY 171101091 T CY171101091 T CY 171101091T CY 1119488 T1 CY1119488 T1 CY 1119488T1
Authority
CY
Cyprus
Prior art keywords
sleep disorder
bases
prevention
treatment
therapeutic
Prior art date
Application number
CY20171101091T
Other languages
English (en)
Inventor
Noriaki Uesaka
Shunji Ichikawa
Takao Nakajima
Original Assignee
Kyowa Hakko Kirin Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co., Ltd. filed Critical Kyowa Hakko Kirin Co., Ltd.
Publication of CY1119488T1 publication Critical patent/CY1119488T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει θεραπευτικό ή/και αποτρεπτικό παράγοντα για τη διαταραχή ύπνου που περιλαμβάνει ως δραστικό συστατικό παράγωγο θειαζολίου που αντιπροσωπεύεται με το γενικό τύπο (I),
CY20171101091T 2005-08-02 2017-10-20 Παραγων για θεραπεια ή/και αποτροπη διαταραχης υπνου CY1119488T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005223547 2005-08-02
PCT/JP2006/315328 WO2007015528A1 (ja) 2005-08-02 2006-08-02 睡眠障害の治療および／または予防剤

Publications (1)

Publication Number Publication Date
CY1119488T1 true CY1119488T1 (el) 2018-03-07

Family

ID=37708808

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101091T CY1119488T1 (el) 2005-08-02 2017-10-20 Παραγων για θεραπεια ή/και αποτροπη διαταραχης υπνου

Country Status (14)

Country Link
US (1) US7928098B2 (el)
EP (1) EP1921077B1 (el)
JP (1) JP5121453B2 (el)
CA (1) CA2617817C (el)
CY (1) CY1119488T1 (el)
DK (1) DK1921077T3 (el)
ES (1) ES2643340T3 (el)
HU (1) HUE034666T2 (el)
LT (1) LT1921077T (el)
PL (1) PL1921077T3 (el)
PT (1) PT1921077T (el)
SI (1) SI1921077T1 (el)
TW (1) TWI457125B (el)
WO (1) WO2007015528A1 (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2629414T3 (es) * 2003-12-26 2017-08-09 Kyowa Hakko Kirin Co., Ltd. Derivados de tiazol
EP1794157B1 (en) 2004-09-22 2014-02-26 H. Lundbeck A/S 2-acylaminothiazole derivatives
US7674912B2 (en) 2005-04-25 2010-03-09 H. Lundbeck A/S Pro-drugs of N-thiazol-2-yl-benzamide derivatives
BRPI0719122A2 (pt) 2006-08-24 2013-12-10 Novartis Ag Compostos orgânicos
KR20090053923A (ko) 2006-09-22 2009-05-28 노파르티스 아게 헤테로시클릭 유기 화합물
BRPI0720452A2 (pt) 2006-12-20 2014-01-14 Novartis Ag Compostos orgânicos
MX2011000788A (es) 2008-07-23 2011-03-21 Kyowa Hakko Kirin Co Ltd Agente terapeutico para migraña.
TWI548411B (zh) 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
UA113383C2 (xx) * 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів
UA110097C2 (uk) 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
CN106905311A (zh) * 2010-08-27 2017-06-30 钙医学公司 调节细胞内钙的化合物
UY34832A (es) 2012-05-31 2013-12-31 Phenex Pharmaceuticals Ag TIAZOLES SUSTITUIDOS POR CARBOXAMIDA O SULFONAMIDA Y DERIVADOS RELACIONADOS COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUÉRFANO RORy (lambda)
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
US10314820B2 (en) 2014-12-04 2019-06-11 Procomcure Biotech Gmbh Imidazole-based heterocyclic compounds
EP3226858B1 (en) 2014-12-04 2021-02-03 Procomcure Biotech GmbH Imidazole-based antimicrobial agents
JOP20200093A1 (ar) 2015-01-09 2017-06-16 Kyowa Kirin Co Ltd طريقة لإنتاج مشتق ثيازول
WO2016160938A1 (en) * 2015-04-02 2016-10-06 Abbvie Inc. N-(1,3-thiazol-2-yl)pyrimidine-5-carboxamides as trpv3 modulators
US20190111069A1 (en) * 2016-04-15 2019-04-18 Oxford University Innovation Limited Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders
CN109293652B (zh) * 2017-07-24 2021-10-22 四川科伦博泰生物医药股份有限公司 一种取代的噻唑衍生物及其用途
US12215102B2 (en) 2023-02-28 2025-02-04 Reglagene, Inc. Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2677356B1 (fr) 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
CA2302417A1 (en) 1997-10-27 1999-05-06 Takeda Chemical Industries, Ltd. Adenosine a3 receptor antagonists
WO1999064418A1 (en) 1998-06-05 1999-12-16 Novartis Ag Aryl pyridinyl thiazoles
JP3333774B2 (ja) 1999-04-23 2002-10-15 武田薬品工業株式会社 ５−ピリジル−１，３−アゾール化合物、その製造法及び用途
HUP0203766A3 (en) 1999-04-23 2008-01-28 Takeda Pharmaceutical 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof and pharmaceutical compositions containing them
JP2002302488A (ja) * 2000-03-30 2002-10-18 Takeda Chem Ind Ltd 置換１，３−チアゾール化合物、その製造法および用途
EP1268474A2 (en) 2000-03-30 2003-01-02 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
US6643966B2 (en) * 2001-03-05 2003-11-11 Anthony J. Schmitt Banner sign display stand
JPWO2002079204A1 (ja) 2001-03-28 2004-07-22 協和醗酵工業株式会社 ８−チアゾリル［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
TWI330183B (el) 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
WO2003039451A2 (en) 2001-11-08 2003-05-15 Fujisawa Pharmaceutical Co., Ltd. Thiazole pyridazinones as adenosine antagonists
GB0130705D0 (en) 2001-12-21 2002-02-06 Glaxo Group Ltd Chemical compounds
TW200524887A (en) 2003-10-27 2005-08-01 Lundbeck & Co As H N-thiazol-2-yl-benzamide derivatives
ES2629414T3 (es) 2003-12-26 2017-08-09 Kyowa Hakko Kirin Co., Ltd. Derivados de tiazol
EP1794157B1 (en) 2004-09-22 2014-02-26 H. Lundbeck A/S 2-acylaminothiazole derivatives
EP1894930A4 (en) 2005-06-23 2010-06-23 Kyowa Hakko Kirin Co Ltd THIAZOLE DERIVATIVE

Also Published As

Publication number Publication date
JPWO2007015528A1 (ja) 2009-02-19
ES2643340T3 (es) 2017-11-22
DK1921077T3 (en) 2017-10-23
SI1921077T1 (sl) 2017-11-30
PL1921077T3 (pl) 2018-01-31
EP1921077A4 (en) 2009-01-28
WO2007015528A1 (ja) 2007-02-08
JP5121453B2 (ja) 2013-01-16
CA2617817A1 (en) 2007-02-08
TWI457125B (zh) 2014-10-21
TW200740434A (en) 2007-11-01
CA2617817C (en) 2014-05-27
HUE034666T2 (hu) 2018-02-28
LT1921077T (lt) 2017-09-25
US7928098B2 (en) 2011-04-19
US20100152162A1 (en) 2010-06-17
EP1921077B1 (en) 2017-07-26
PT1921077T (pt) 2017-10-26
EP1921077A1 (en) 2008-05-14

Similar Documents

Publication Publication Date Title
CY1119488T1 (el) Παραγων για θεραπεια ή/και αποτροπη διαταραχης υπνου
CY1121125T1 (el) Συνθεσεις για τη θεραπευτικη αντιμετωπιση του πονου και/ή της φλεγμονης
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
CY1121144T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
CY1118232T1 (el) Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
CY1110835T1 (el) Διφαινυλ παραγωγα και η χρηση τους στη θεραπεια της ηπατιτιδας c
CY1116688T1 (el) Τροποποιητες φαρμακοκινητικων ιδιοτητων θεραπευτικων ειδων
CY1106679T1 (el) Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα
SMT201300109B (it) Imidazopiridazincarbonitrili utili come inibitori di chinasi
CY1108267T1 (el) Ενωσεις που επηρεαζουν τη γλυκοκιναση
CY1112886T1 (el) Ανοσοκατασταλτικος παραγοντας ο οποιος περιλαμβανει μια ετεροκυκλικη ενωση ως δραστικο συστατικο
CY1109656T1 (el) Υποκατεστημενα παραγωγα μορφολινης και θειομορφολινης
CY1119118T1 (el) Θεραπευτικος παραγων για τις διαταραχες της διαθεσης
UY27226A1 (es) Pirazolopirimidinas como agentes terapéuticos
CY1112860T1 (el) 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντικαρκινικοι παραγοντες
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
CY1105362T1 (el) Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα
CY1113314T1 (el) (3-αρυλ-πιπεραζιν-1-υλ) παραγωγα της 6,7-διαλκοξυκιναζολινης, 6,7-διαλκοξυφθαλαζινης και 6,7-διαλκοξυϊσοκινολινης
UY32123A (es) Derivados de n - (sustituido) - 4 - (but-2-iniloxi) - benzamida, sus racematos, diastereòmeros, enantiòmeros y las sales de los mismos y aplicaciones
EA200801199A1 (ru) Ингибиторы киназы
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
CY1113439T1 (el) Ενωση αζολιου
CY1113175T1 (el) Ενωση σουλφοναμιδης και εφαρμογη αυτης
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
CY1119483T1 (el) Θεραπευτικος παραγων για τις αγχωδεις διαταραχες